PTO/SB/14 (08-05) Approved for use through 07/31/2005. OMB 0651-0032

U.S. Palent and Trademark Office, U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Δnnli	Application Data Sheet 37 C				4 37 CFR 1.76 Attorn			orney Docket Number			51326-00019			
~bbii	out.on De	iii oiii		J. IX	Application Number									
Title of Invention Recombinant Intracellular Pathogen Immunogenic Compositions and Methods for Use The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the														
bibliogra This doc	phic data arrar	iged in a f complet	format spe led electro	cified by nically a	the Un	ited States I mitted to the	Patent	and Tra	demark O	office as o	outlined in 37 C			
	cy Orde													
												Secrecy Order pur electronically.)	suant to	
Appli	cant Info	ormat	ion:											
Applic	ant 1											Remove		
Applic	ant Author	ity 💿 ln	ventor	Ores	gal Rep	presentativ	e unde	er 35 t	J.S.C. 11	7	Party of in	terest under 35 U.S	.C. 118	
Prefix	Given Nar	ne			M	iddle Nar	ne			Fami	ly Name		Suffix	
	Marcus				A					Horw	_			
_	ence Inform	nation (Select (<u> </u>	\sim	Residency	<u> </u>	\sim	n US Re			US Military Service		
City	Los Angele	\$			State	Province	· 0	A.	Countr	y of R	esidence i	US		
Citizer	nship under	37 CFI	R 1.41(b) i	US									
Mailin	g Address (of Appli	icant:											
Addre	ss 1		1275 Stra	adella F	Road									
Addre	ss 2													
City	Los Ar	geles						Stat	e/Provir	nce	CA			
Postal	Code	- 1	90077				Cou	ntryi	US					
Applic	ant 2											Remove		
Applic	ant Author	ity	ventor	OLeg	gal Rep	resentativ	e unde	er 35 t	J.S.C. 11	7	Party of In	terest under 35 U.S	C. 118	
Prefix	Given Nar	ne			Middle Name					Fami	Suffix			
	Gunter									Harth				
Resid	ence Inform	nation (Select (One)	⊙ us	Residency	, () No	n US Re	sidency	O Activ	US Military Service		
City	Los Angele	s			State	Province	0	:A	Countr	y of R	esidence i	US		
Citizer	nship under	37 CF	R 1.41(b) i	US									
Mailin	g Address	of Appli	icant:											
Addre	ss 1		1525 Sav	vtelle B	lvd., #1	16								
Addre	ss 2													
City	Los Ar	ngeles						Stat	e/Provir	nce	CA			
Postal	Code		90025				Cou	ntryi	US					
Applic	ant 3											Remove		
Applic	ant Author	ity (•) In	ventor	OLeg	gal Rep	presentativo	e unde	er 35 t	J.S.C. 11	7	Party of In	terest under 35 U.S.	C. 118	
Prefix Given Name					М	Middle Name				Family Name			Suffix	
	Michael				v	-				Tulliu	is			
Resid	Residence Information (Select One) US Residency Non US Residency Active US Military Service													

Encino

State/Province

CA

Country of Residence i US

PTO/88/14 (08/05)

Approved for use through 07/31/2005. OMB 0651-0032 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

	Once the r	aperwo	IK PURBUCION ACTOR I	1990, NO PER	sons are req	CRECO IO IO	espons	ID # CORRCOR	ORI OF ETION	MICH LINESS	E CONTAINS	2 42 80 OW	o control number
Application Data Sheet 37 CFR 1.76					Attorney Docket Number			umber	51326	00019			
					Application Number								
Title of Invention Recombinant Intracellular Pathogen Immunogenic Compositions and Methods									Methods fo	or Use			
Citizensh	Citizenship under 37 CFR 1.41(b) i US												
Mailing A	Address o	of Ap	plicant:										
Address	1		5229 Balboa B	3lvd., #13	i e								
Address	Address 2												
City	City Encino State/Province CA												
Postal C	Countryi US												
All Inventors Must Be Listed - Additional Inventor Information blocks may be generated within this form by selecting the Add button. Add													

Correspondence Information:											
Enter either Customer Number or complete the Correspondence Information section below. For further information see 37 CFR 1.33(a).											
An Address is being provided for the correspondence Information of this application.											
Customer Number	Customer Number 45200										
Email Address mglasky@prestongates.com Add Email Remove Email											
Email Address	mnadal@prestongates.com	Add Email	Remove Email								

Application Information:

Title of the Invention	Recombinant Intracellular Pathogen Immunogenic Compositions and Methods for Use								
Attorney Docket Number	51326-00019		Small Entity Status Claimed 🗸						
Application Type	Nonprovisional								
Subject Matter	Utility								
Suggested Class (if any)			Sub Class (if any)						
Suggested Technology C	enter (if any)								
Total Number of Drawing	Sheets (if any)	13	Suggested Figure for Publication (if any) 7						
Publication Information:									
Request Early Publica	tion (Fee required	at time of Reques	37 CFR 1.219)						
and certify that the inv	vention disclosed in	n the attached app	application not be published under 35 U.S.C. 1 lication has not been and will not be the subject agreement, that requires publication at eighteen	of an					

Representative Information:

Representative information should be provided for all practitioners having a power of attorney in the application. Providing this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32). Enter either Customer Number or complete the Representative Name section below. If both sections are completed the Customer Number will be used for the Representative Information during processing.

Application Da	ta She	et 37 CFR 1.76	App	lication	Number					
Title of Invention	Recon	nbinant Intracellular Pal	thogen	Immuno	genic Compositio	ns and M	ethods for U	se		
Please Select One:	-1	Customer Number	- 1/	∩ USE	Patent Practitioner	10	US Renres	entative (37 CFR 1	1.9)	
Customer Number		45200		<u> </u>	uicii i iuomoro	10	OO TOPICS	Situate (5) Of ICT	1.5)	
Customer Number		43200								
Domestic Pric	rity I	nformation:								
application data shee	t constit	plicant to claim benefit utes the specific referer e made part of the spec	nce rec	quired by						
Prior Application	Status	Pending						Remove		
Application Nun	nber	Continuity 1	Type		Prior Application	on Numb	er Filing	Filing Date (YYYY-MM-DD)		
		a 371 of international	ti		PCT/US2004/34	206	2004-1	0-15		
Prior Application	Status	Expired						Remove		
Application Nun	nber	Continuity	Type		Prior Application	on Numb	er Filing	Date (YYYY-MN	/I-DD)	
PCT/US2004/34206		non provisional of			60512565		2003-1	0-16		
Additional Domesti the Add button.	c Priori	ty Data may be gen	erate	d within	this form by se	electing	- 1	Add		
Foreign Priori	ty Inf	ormation:								
		plicant to claim benefit ormation in the applicat								
								Remove		
Application Nun	nber	Country	y i		Parent Filing D	ate (YYY	Y-MM-DD)	Priority CI	aimed	
								● Yes ○	No	
Additional Foreign Add button.	Priority	Data may be genera	ated w	ithin thi	s form by selec	ting the	- 1	Add		
Assignee Info	rmati	on:								
		ne application data she ment recorded in the O		s not sub	stitute for complic	ance with a	any requirem	ent of part 3 of Tit	e 37	
Assignee 1								Remove		
If the Assignee is a	n Organ	nization check here.	-	Z						
Organization Name	T	he Regents of the Unive	ersity o	of Californ	nia					
Mailing Address I	nforma	tion:								
Address 1		1111 Franklin Street	1111 Franklin Street, 5th Floor							
Address 2										
City		Oakland			State/Provin	ce	CA			
Country i US					Postal Code		94607-5200	1		
Phone Number					Fax Number					

PTO/SR/14 (08.05)

Approved for use through 07/31/2005. OMB 0651-0032 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if contains a valid OMB control number

Application Da	to Cha	et 37 CFR 1.76	Attorney Docket Number	51326-00019	.0019				
Application Da	ita Sile	et 37 CFR 1.76	Application Number						
Title of Invention	Recom	binant Intracellular Pa	thogen Immunogenic Composit	ons and Methods for	Use				
Email Address									
Additional Assignee Data may be generated within this form by selecting the Add									

Signature: A signature of the applicant or representative is required in accordance with 37 CFR 1.33 and 10.18, Please see 37 CFR 1.4(d) for the form of the signature. Signature /Michelle S. Glasky/ Date (YYYY-MM-DD) First Name Michelle S Last Name Glasky Registration Number 54124

This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. 9. 36-379) inequases that jour to given certain information is connection with jour submission of the attracted from related to a potent application of post application of post and post application of the information is 30 U.S.C. (20)(2); (2) Intrinsiting of the information is solded in such post application post post in which the information is used by the U.S. Patient and Traderess Office on postess and post application of post in 1900 post of post application of post in 1900 post application of post in 1900 post in 1900 post application of post in 1900 post in 1900 post in 1900 post in 1900 post application of post in 1900 post application of post in 1900 post in

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent atlowed under the Freedom of Information Act (5 U.S.C. 552), and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement recordations.
- A moord in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the inclividual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipitate of information in an order to reproduce of information in an order to perform a contract. Projection of information in a record of information in the souther of records may be disclosed.
- as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Ammisstator, General Services, or hisher designed, using an inspection of records conducted by GSA as part of that apency's responsibility to recommend improvements in section amongement practices and programs, under authority of 44 U.S.C. 2004 and 2006. Such disclosus shall be used in accordance with the CSA regulations potenting impaction of records for the proposal, and any other researd (i.e., GSA or Commerce) directive. Such the CSA regulations of potenting impaction of records for the proposal, and any other researd (i.e., GSA or Commerce) directive.
- 8. A moord from this system of records may be disclosed, as a routine use, b the public after either publication of the application parameter to 30 till \$6. C195 per season or of partner parameter 50 till \$6. C195. Further, a record may be disclosed, subject to the inflations of 37 CRT 114, as a routine use, to the public if the record was tilled in an application which became abundanced or in which the proceedings were thermated and within applications in effective or in second transfer or in a second transfer or in the procedure of the procedure of the procedure or in second transfer or in the procedure or in second transfer or in the procedure or in the procedure or in second transfer or in the procedure or in the procedure or in the procedure or in second transfer or in the procedure or i
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.